Apex’s partner for driving simulation studies, Cognitive Research Corporation, authored an article (https://doi.org/10.1111/cts.13145) about a clinical trial assessing the effect of Rapastinel on driving performance (NCT03814733). The trial, in which 107 healthy participants were enrolled, was conducted at two study centers including the Long Beach, CA location of Collaborative Neuroscience Research (CNS). The results of the investigation show that Rapastinel 900 and 1800 mg did not significantly affect simulated driving performance compared to placebo. Both rapastinel doses resulted in significantly less impaired driving compared to alprazolam or ketamine; ketamine significantly impaired driving compared to placebo.
Driving Simulation Study Conducted by CNS Recently Published in Clinical and Translational Science